Charles River Laboratories International (NYSE:CRL) Upgraded at Barclays

Barclays upgraded shares of Charles River Laboratories International (NYSE:CRL) from an equal weight rating to an overweight rating in a research report released on Thursday, MarketBeat reports. The brokerage currently has $195.00 price objective on the medical research company’s stock, up from their previous price objective of $165.00.

CRL has been the topic of a number of other reports. Evercore ISI lifted their price target on Charles River Laboratories International from $180.00 to $190.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. JPMorgan Chase & Co. raised their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Citigroup upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and upped their price target for the company from $142.00 to $195.00 in a research report on Tuesday, September 9th. Finally, Wall Street Zen raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Monday, September 29th. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $179.93.

Charles River Laboratories International Stock Up 1.3%

Shares of NYSE:CRL opened at $177.56 on Thursday. The company has a fifty day moving average of $159.47 and a 200-day moving average of $147.29. The company has a market capitalization of $8.74 billion, a PE ratio of -133.51, a price-to-earnings-growth ratio of 4.74 and a beta of 1.50. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $230.02.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the business posted $2.80 EPS. On average, equities analysts predict that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the sale, the executive vice president directly owned 24,116 shares in the company, valued at $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in shares of Charles River Laboratories International by 5.1% in the 1st quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock worth $644,980,000 after acquiring an additional 208,586 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Charles River Laboratories International by 29.1% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after purchasing an additional 516,521 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC grew its stake in Charles River Laboratories International by 8.0% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company’s stock worth $293,555,000 after purchasing an additional 144,732 shares during the period. Ariel Investments LLC increased its holdings in Charles River Laboratories International by 28.6% in the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after purchasing an additional 314,572 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Charles River Laboratories International by 11.6% in the second quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock worth $187,712,000 after purchasing an additional 128,785 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).